HK1214552A1 - 在腎損傷的受試者中用泊馬度胺治療癌症 - Google Patents

在腎損傷的受試者中用泊馬度胺治療癌症 Download PDF

Info

Publication number
HK1214552A1
HK1214552A1 HK16102558.2A HK16102558A HK1214552A1 HK 1214552 A1 HK1214552 A1 HK 1214552A1 HK 16102558 A HK16102558 A HK 16102558A HK 1214552 A1 HK1214552 A1 HK 1214552A1
Authority
HK
Hong Kong
Prior art keywords
pomalidomide
cancer
subject
treatment
impaired subject
Prior art date
Application number
HK16102558.2A
Other languages
English (en)
Chinese (zh)
Inventor
克勞迪婭．伊芙．卡塞拉
克劳迪娅．伊芙．卡塞拉
Original Assignee
细胞基因公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 细胞基因公司 filed Critical 细胞基因公司
Publication of HK1214552A1 publication Critical patent/HK1214552A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16102558.2A 2012-11-05 2013-11-04 在腎損傷的受試者中用泊馬度胺治療癌症 HK1214552A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261722722P 2012-11-05 2012-11-05
US61/722,722 2012-11-05
US201361764466P 2013-02-13 2013-02-13
US61/764,466 2013-02-13
PCT/US2013/068237 WO2014071280A1 (en) 2012-11-05 2013-11-04 Treatment of cancer with pomalidomide in a renally impaired subject

Publications (1)

Publication Number Publication Date
HK1214552A1 true HK1214552A1 (zh) 2016-07-29

Family

ID=50628132

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16102558.2A HK1214552A1 (zh) 2012-11-05 2013-11-04 在腎損傷的受試者中用泊馬度胺治療癌症

Country Status (15)

Country Link
US (1) US20150297579A1 (enExample)
EP (1) EP2914112A4 (enExample)
JP (1) JP2015535291A (enExample)
CN (1) CN104902754A (enExample)
AU (1) AU2013337352A1 (enExample)
BR (1) BR112015010039A2 (enExample)
CA (1) CA2889987A1 (enExample)
EA (1) EA201590883A1 (enExample)
HK (1) HK1214552A1 (enExample)
IL (1) IL238563A0 (enExample)
MX (1) MX2015005548A (enExample)
NI (1) NI201500063A (enExample)
PH (1) PH12015501002A1 (enExample)
SG (1) SG11201503456TA (enExample)
WO (1) WO2014071280A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201591902A1 (ru) * 2013-04-02 2016-02-29 Селджин Корпорейшн Способы и композиции, использующие 4-амино-2-(2,6-диоксо-пиперидин-3-ил)изоиндолин-1,3-дион для лечения и контроля злокачественных опухолей центральной нервной системы
CA3025145A1 (en) * 2015-05-22 2016-12-01 Translational Drug Development Llc Benzamide and active compound compositions and methods of use
CN105456232A (zh) * 2015-09-08 2016-04-06 刘剑 一种泊马度胺速溶膜剂及其制备方法
CN109071460B (zh) * 2016-03-02 2022-08-09 转化药物开发有限责任公司 氨基苯并咪唑衍生物
WO2018013689A1 (en) * 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
CN108721304B (zh) * 2017-04-17 2020-10-16 北京大学 用于治疗肿瘤的药物组合物及其用途
AU2018328308A1 (en) * 2017-09-06 2020-04-16 Translational Drug Development, Llc Aminobenzimidazole derivatives, treatments, and methods of inhibiting histone deacetylase
AR119715A1 (es) 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona
GB202012160D0 (en) * 2020-08-05 2020-09-16 Vicore Pharma Ab New compositions
EP4479082A2 (en) * 2022-02-15 2024-12-25 The Broad Institute, Inc. Cell-type specific targeting contractile injection system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
JP5339588B2 (ja) * 2008-11-10 2013-11-13 国立大学法人 新潟大学 サリドマイドまたはその誘導体を有効成分とする統合失調症の治療薬
JP5553275B2 (ja) * 2010-03-31 2014-07-16 国立大学法人金沢大学 金属錯体およびこれを有効成分として含有する抗がん剤
MX2013012083A (es) * 2011-04-18 2014-04-16 Celgene Corp Biomarcadores para el tratamiento de mieloma multiple.
CN103688176A (zh) * 2011-04-29 2014-03-26 细胞基因公司 利用cereblon作为预报因子治疗癌和炎性疾病的方法

Also Published As

Publication number Publication date
EA201590883A1 (ru) 2015-09-30
CA2889987A1 (en) 2014-05-08
SG11201503456TA (en) 2015-05-28
BR112015010039A2 (pt) 2017-07-11
WO2014071280A1 (en) 2014-05-08
CN104902754A (zh) 2015-09-09
EP2914112A1 (en) 2015-09-09
PH12015501002A1 (en) 2015-07-27
US20150297579A1 (en) 2015-10-22
EP2914112A4 (en) 2016-06-15
NI201500063A (es) 2015-09-10
MX2015005548A (es) 2016-01-15
AU2013337352A1 (en) 2015-05-21
JP2015535291A (ja) 2015-12-10
IL238563A0 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
HK1214552A1 (zh) 在腎損傷的受試者中用泊馬度胺治療癌症
HK1223319A1 (zh) 用於治疗或预防眼科病的方法
MX2015013166A (es) Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
WO2014178931A8 (en) Sobetirome in the treatment of myelination diseases
MY160445A (en) Dual Variable Domain Immunoglobulins And Uses Thereof
UA117451C2 (uk) Терапевтично активні сполуки і способи їх застосування
IN2015DN00450A (enExample)
HK1203356A1 (en) Pharmaceutical combinations comprising a thionucleotide analog
CA2875824C (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
WO2014089209A3 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
WO2014153056A3 (en) Cancer treatment using antibodies that bing cell surface grp78
WO2013188847A8 (en) Compositions and methods for transmucosal absorption
WO2015191934A8 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
MX356210B (es) Formulaciones de polimero acrilico.
JP2015535291A5 (enExample)
WO2014164285A3 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
WO2014153385A3 (en) Methods of treating metabolic disorders
MX2019000677A (es) Células miméticas de células b.
WO2018102261A3 (en) Boronic derivatives hydroxamates as anticancer agents
EA201500363A1 (ru) Человеческие анти-vegfr-2/kdr-антитела
MX348412B (es) Métodos de usar sns-595 para el tratamiento de sujetos con cáncer con actividad reducida de brca2.
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
WO2012153253A3 (en) Aromatic compounds and metal complexes thereof
WO2012173781A3 (en) Methods of treating glucose metabolism disorders